Filter articles using the following links

GenSight Biologics receives MHRA approval to initiate Phase I/II PIONEER clinical trial of GS030 gene therapy in Retinitis Pigmentosa

JP Morgan 36th Annual Healthcare Conference, San Francisco (CA), USA

Guggenheim Securities 5th Annual Boston Healthcare Conference 2017, Boston, MA, USA

GenSight Biologics reports positive long-term visual acuity gains and safety results from Phase I/II Study of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)

The Stifel Nicolaus Weisel Healthcare Conference 2017, New York, NY, USA

American Academy of Ophthalmology, New Orleans (LA)

Ophthalmology Innovation Summit @ AAO, New Orleans (LA)

GenSight Biologics to Participate in Multiple Conferences in November

GenSight Biologics Reports its Cash Position as of September 30, 2017

GenSight Biologics Appoints Barrett Katz as Chief Medical Officer